Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of use: not for treating type 1 diabetes mellitus or diabetic ketoacidosis.
DAPA-MI (DAPAgliflozin effects in patients without diabetes with Myocardial Infarction) is an international, multi-center, double-blinded registry-based randomized controlled trial designed to assess ...
Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular ...
Treatment with dapagliflozin led to a statistically significant improvement in HbA1c compared with placebo. The Food and Drug Administration (FDA) has expanded the approval of Farxiga ® (dapagliflozin ...
AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
WILMINGTON, Del.--(BUSINESS WIRE)--New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and ...
AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving standard of care. Heart failure (HF) is a ...
Farxiga (dapagliflozin) is a brand-name tablet that’s prescribed for different uses in adults with type 2 diabetes, heart failure, or kidney disease. Farxiga interacts with some other drugs and ...
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure ...
AstraZeneca AZN announced that the FDA has issued a complete response letter (“CRL”) to its supplemental new drug application (sNDA) for SGLT2 inhibitor, Farxiga (dapagliflozin). The sNDA sought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results